The outgoing CEO of Cambridge biotech OvaScience saw her total compensation last year decline more than 90 percent from the prior year, mostly due to a sharp drop in the firm’s stock value.
CEO Michelle Dipp has never taken a salary since she co-founded OvaScience (Nasdaq: OVAS) in 2011 to develop methods for women to get pregnant that are more reliable that in-vitro fertilization. Instead, she is paid purely in shares of company stock. The total value of those shares last year was valued at $436,000 — less than 8 percent of $5.6 million in stock and options she received as payment in 2014.
CEO Michelle Dipp has never taken a salary since she co-founded OvaScience (Nasdaq: OVAS) in 2011 to develop methods for women to get pregnant that are more reliable that in-vitro fertilization. Instead, she is paid purely in shares of company stock. The total value of those shares last year was valued at $436,000 — less than 8 percent of $5.6 million in stock and options she received as payment in 2014.
